Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
Trinity Medical Devices said yesterday that it paid $3.35 million for CAS Medical System‘s line of neonatal intensive care disposables.
The deal includes a an additional $400,000 milestone pegged to sales targets over the next 12 months, Parsippany, N.J.-based Trinity said. Read more
Wound care company Nuo Therapeutics said yesterday that a federal court in Delaware approved a bankruptcy plan that would either see it continue as an independent company or become 95% owned by lender Deerfield Management.
Gaithersburg, Md.-based Nuo filed for Chapter 11 bankruptcy protection in January, 2 years after raising $35 million from Deerfield. Formerly known as Cytomedix, the company makes the Aurix hematogel, which is designed to stimulate the body’s native mechanisms to heal wounds. Read more
The FDA today released a safety letter warning against the use of OxySure Therapeutic’s Portable Emergency Oxygen System model 615.
The safety communication comes based on complaints of adverse events related to insufficient oxygen flow, re-breathing of exhaled gases, burns, bruising and exposure to chemicals. Read more
A New Jersey appeals court today upheld a $11.1 million jury award against Johnson & Johnson’s Ethicon subsidiary in a case concerning injuries caused by the company’s Prolift vaginal mesh.
The plaintiff in the case claimed the product caused debilitating nerve pain and said that better labeling and warnings could have prevented injuries. The plaintiff added that the product resulted in multiple complications which required intensive medical treatment and numerous operations, according to court documents. Read more
Retina Implant said today that it won CE Mark approval in the European Union for the latest iteration of its subretinal implant for patients blinded by retinitis pigmentosa.
The Alpha AMS is the next-generation version of the Alpha IMS, which won CE Mark approval back in July 2013. The Reutlingen, Germany-based company said the new device increases the number of pixels from 1,500 to 1,600, claiming the title for most electrodes of any neuroprosthetic implant. Read more